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Abstract Osteoarthritis (OA), a disease affecting differ-
ent patient phenotypes, appears as an optimal candidate for
personalized healthcare. The aim of the discussions of the
European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) working group
was to explore the value of markers of different sources in
defining different phenotypes of patients with OA. The
ESCEO organized a series of meetings to explore the
possibility of identifying patients who would most benefit
from treatment for OA, on the basis of recent data and
expert opinion. In the first meeting, patient phenotypes were
identified according to the number of affected joints,
biomechanical factors, and the presence of lesions in the
subchondral bone. In the second meeting, summarized in
the present article, the working group explored other
markers involved in OA. Profiles of patients may be defined
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according to their level of pain, functional limitation, and
presence of coexistent chronic conditions including frailty
status. A considerable amount of data suggests that mag-
netic resonance imaging may also assist in delineating
different phenotypes of patients with OA. Among multiple
biochemical biomarkers identified, none is sufficiently
validated and recognized to identify patients who should be
treated. Considerable efforts are also being made to identify
genetic and epigenetic factors involved in OA, but results
are still limited. The many potential biomarkers that could
be used as potential stratifiers are promising, but more
research is needed to characterize and qualify the existing
biomarkers and to identify new candidates.
Key Points
Osteoarthritis affects different patient phenotypes
with heterogeneous clinical presentation, rate of
progression, and response to therapy, and thus
appears as an optimal candidate for personalized
medicine.
The level of pain, functional limitation, and presence
of coexistent chronic conditions including frailty
status should be considered to guide treatment
decisions.
Magnetic resonance imaging-based diagnosis could
be used in drug development and in clinical practice
to identify patients more likely to benefit from
treatment.
Promising potential biomarkers (e.g., biochemical,
genetic, epigenetic) currently under investigations
could be used in the near future to guide clinical
decision making.
1 Introduction
As non-communicable diseases increase with the rise in
life expectancy and with the changes in lifestyle, the
traditional approach to their management should be
reconsidered. Current medicine is still largely based on
the ‘one-size-fits-all’ model where patients diagnosed
with the same condition often are prescribed the same
medication at the same dose. For some medications, this
model potentially can lead to poor response, preventable
occurrence of side effects, and increased healthcare costs.
For these reasons, a more patient-centric or personal-
ized approach of medical practice has been proposed and
the conventional model is being replaced by new
approaches in which the health of the patients can be
managed according to their individual biologic or risk
factors. The concept of ‘stratified medicine’ refers to this
targeting of treatments (including pharmacological and
non-pharmacological interventions) according to the bio-
logical or risk characteristics shared by subgroups of
patients. The potential to use biomarkers for identifying
patients with the greatest chance of benefit and the lowest
risk of experiencing adverse events in response to a given
therapy is anticipated to have a major effect on both
clinical practice (e.g., choice of treatment, dosing, or
duration of treatment) and the development of new drugs
and diagnostics [1, 2].
Osteoarthritis (OA) is a common slowly progressive
condition that may affect the structure of all joint tissues,
and is a major cause of pain and chronic disability in the
elderly [3]. The lack of a universal definition of OA is
probably because of the complexity of processes under-
lying its pathogenesis [4] and to the diversity in clinical
presentation, rate of disease progression, pattern of joint
involvement, and joint tissue affected [5]. Considering
this marked heterogeneity, it appears unlikely that one
treatment will benefit all phenotypes of patients. OA thus
appears as an optimal candidate for personalized
medicine.
The ESCEO (European Society for Clinical and Eco-
nomic Aspects of Osteoporosis and Osteoarthritis) has
previously explored a variety of pivotal topics in OA,
including the question of how best to define responders to
treatment for drug development [4] and the value of
magnetic resonance imaging (MRI) in the diagnosis of the
disease and the prediction of the hard outcome of joint
replacement surgery [6].
An ESCEO working meeting convened in October 2012
discussed the value of biomarkers currently investigated in
drug development in OA with a focus on the potential
avenues for future research [7]. In 66 relevant publications,
numerous candidate biomarkers from multiple sources
were identified. Some were considered promising but none
of the best candidates has entered clinical use.
In a meeting held in October 2013, an ESCEO-EUGMS
(European Union Geriatric Medicine Society) working
group discussed the possibility of identifying patients who
would most benefit from treatment for OA, to better ori-
entate research and to identify relevant outcomes in clinical
trials. Patient profiles were identified according to the
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number of affected joints, biomechanical factors, and the
presence of lesions in the subchondral bone [8].
In this second meeting held in May 2014, the working
group explored other markers involved in OA that could be
used to define patients to be treated, such as imaging,
clinical, biochemical, genetic, and epigenetic markers. This
is the subject of the present article.
2 Process and Outcomes
As in previous initiatives and publications, the ESCEO
working group consisted of clinical scientists and experts
in the field of OA in academia and the pharmaceutical
industry, and representatives of national or European
licensing authorities giving their contribution on a personal
basis. Members of the group were asked to prepare a full
review of the literature on imaging markers (JMP), clinical-
biochemical markers (MH), stratified medicine in OA
(CC), genetic-epigenetic markers (ED), and the association
of OA with frailty status (SM).
They identified relevant articles, reviews, and
abstracts in a search of PubMed/MEDLINE and
EMBASE for English language articles published
between 1990 and October 2014. The initial search
strategy included the terms osteoarthritis, risk factor,
predictor, progression, guidelines, biomarkers, MRI, and
phenotype. Separate sub-searches were also performed
using a cross search of the above terms combined, and
additional references were selected from the reference
lists of selected articles and the presentations made
during the working meeting. The narrative is therefore
largely based upon expert opinion. Relevant items were
selected by the authors according to their quality and
pertinence for discussion by the ESCEO working group.
After the presentations given at the working meeting, a
comprehensive discussion was held within the group and
shared conclusions were reached. Two electronic con-
sultation rounds occurred on the draft manuscript to
achieve a final consensus.
3 Risk Factors for Progression and Predictors
of Response to Treatments
3.1 Risk Factors for Progression
Increasing our knowledge regarding the predictors of pro-
gression of OA is important for optimal treatment alloca-
tion and clinical investigations of new therapies [9]. Not all
patients will progress symptomatically, radiologically, or
to joint replacement and treatments need to be focused to
those most at need.
A number of risk factors for the progression of OA have
been identified including obesity, radiographic features,
biomechanical derangement, multi-joint OA, and synovi-
tis/effusion [10, 11]. In a study on 561 patients, although
more than half of the patients had stable Kellgren–Lawr-
ence grades over 15 years, patients with a baseline Kell-
gren–Lawrence grade 1 were twice as likely to progress as
those with a baseline Kellgren–Lawrence grade 0 [12]. A
systematic review to identify risk factors for radiographic
progression showed that knee malalignment was an inde-
pendent risk factor for the progression of knee OA [11]. A
review of 36 high-quality studies was performed to provide
an overview of prognostic factors of knee OA progression
[9]. While sex, knee pain, radiologic severity, knee injury,
quadriceps strength, and regular sport activities did not
seem to be predictive, the best evidence synthesis yielded
strong evidence that the serum levels of hyaluronic acid, a
marker of synovial inflammation, and generalized OA (i.e.,
different joints affected at the same time) are predictive for
the progression of knee OA [9]. In studies focussing on
patient-reported outcomes (pain or activity limitations), as
opposed to radiographic progression, prognostic factors
that were identified included radiographic, biomechanical,
biological, and clinical factors but also psychological and
social factors [13, 14]. Most of these findings need to be
validated and interactions between individual potential
predictors of progression need to be identified, providing a
direction for future research.
3.2 Predictors of Response to Treatment
However, predictors for progression of the disease and
need for treatment may not be the same as the predictors of
response to treatment. Current OA treatment includes non-
pharmacological therapies, such as physical therapy,
weight loss in obese patients or device-based treatments,
and pharmacologic therapies, primarily intended to allevi-
ate pain and improve/preserve functional ability. When all
previous modalities have failed, surgery such as joint
replacement is the main option. A recent algorithm was
developed to advise on the possible stepwise approach to
the sequence of interventions [15]. All current treatments
are symptom-modifying drugs as there are no licensed
treatments that prevent the progression of the disease.
Disease-modifying OA drugs (DMOADs) have therefore
become a major focus of research, but their development
involves a number of difficulties, including slow disease
progression and a lack of sensitivity of tools recommended
by the regulatory agencies [16]. The current treatments
(except for joint replacement) have at best modest albeit
clinically relevant efficacies, and are sometimes associated
with substantial side effects or costs [17]. Part of this
modest efficacy might be explained by the inclusion of
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heterogeneous groups of OA patients in trials. This high-
lights the need to identify subgroups of patients who might
be responsive to current treatments. Furthermore, all
treatments have associated side effects, stressing the
importance of focusing therapy to patients with the ade-
quate phenotype.
4 Imaging Markers
Radiography is the most commonly used technology and is
recommended by regulatory agencies for assessing
DMOAD. Although radiography has weaknesses, including
a poor sensitivity to changes in cartilage width, it is cheap
and accessible and has been shown to predict the pro-
gression of OA and response to some intra-articular and
oral treatments. The main limitation of plain radiography is
its inability to assess other important joint structures such
as the synovium, meniscus, and bone marrow lesions
(BML). Important progress has been made in the devel-
opment of MRI technology allowing direct, precise, and
reliable assessment of multiple tissues and their changes
over time targeting mostly hip and knee OA. MRI has been
extensively used in a number of studies assessing cartilage
volume loss, BML, synovial membrane thickness, meniscal
extrusion, Hoffa’s fat pad and, less extensively studied,
synovial fluid effusion size.
4.1 Extent of Cartilage Damage
A number of studies suggest that MRI may assist in
delineating different phenotypes of patients with OA. Some
clinical trials have assessed the effect of drugs on articular
structural change over time in patients with knee OA
including licofelone [18], chondroitin sulfate [19], stron-
tium ranelate [20], and sprifermin [21]. In these trials in
patients at a moderate to severe stage of the disease, these
agents were shown to have a beneficial effect on cartilage
volume loss, which was mostly seen at the lateral com-
partment. In a study using data from the OsteoArthritis
Initiative progression cohort, glucosamine plus chondroitin
treatment significantly reduced the cartilage volume loss,
predominantly in patients with mild to moderate knee OA,
but showed no protective effect in those with already
severe disease [22].
This study also suggests that in patients with less
extensive cartilage damage, treatment provided protection
in both medial and lateral compartments.
4.2 Presence of Bone Marrow Lesions
MRI has also been used in a number of studies to select
knee OA patients with BML.
A proof-of-concept trial in knee OA patients evaluated
the effect of zoledronic acid, a bisphosphonate, on BML
change at 1 year. Although data showed a significant
reduction in BML size at 6 months, and a numerical trend
towards a reduction at 12 months, the cartilage volume and
cartilage loss were not assessed [23]. However, other
putative DMOADs were tested for their effects on the
change over time of both BML in the medial compartment
and cartilage volume. Two such drugs were studied, lico-
felone [18] and strontium ranelate [20]. In general, data
showed a strong association for the compounds tested
between BML change and cartilage volume loss in the
same or related topographical site.
4.3 Presence of Meniscal Extrusion
Although the presence of meniscal extrusion has been
shown to be associated with greater cartilage volume loss
and to be a strong marker of OA progression [23, 24], to
our knowledge there has been no clinical trial using MRI
investigating the effect on meniscal extrusion of drug
response to treatment. However, post hoc analyses of
studies exploring the effect of putative DMOADs (li-
cofelone [18], strontium ranelate [25], and chondroitin and
glucosamine sulfate [26]) and one study looking at the
presence of meniscal extrusion in knee OA patients with
neuropathic pain [27], argue in favor of an MRI-based
diagnosis of meniscal extrusion in clinical practice. This
would help physicians identify knee OA patients who are
more likely to benefit from treatment, namely those with
mild to moderate OA with meniscal extrusion, or those
with more symptomatic disease but without meniscal
extrusion. Moreover, co-localized knee structural patholo-
gies such as meniscal extrusion/damage and BML further
increased the risk of cartilage loss [25, 28] highlighting that
the response to treatment of knee OA patients can be
greatly influenced by the presence or absence of multiple
risk factors associated with the progression of structural
changes.
5 Clinical and Biochemical Biomarkers
5.1 Clinical Biomarkers
Among useful clinical markers, the most important and
obvious are the presence and severity of pain and of
functional limitation, which are the primary indications of
licensed medications in OA. Demographic factors (age,
sex, menopause, race/ethnicity, marital status, education)
are important in terms of predicting the need for total joint
replacement but have no role in evaluating the efficacy of a
clinical intervention. As discussed in a previous ESCEO
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meeting, the presence of abnormal biomechanics or severe
malalignment may indicate the use of a certain class of
treatment and predict the lack of efficacy of interventions
(e.g., weight loss or doxycycline [29]) on structural pro-
gression. Inflammation (presence of effusion and/or soft-
tissue swelling) is a predictor of progression to total joint
replacement [30]. Some inconsistent data suggest that the
presence of effusion is predictive of the efficacy of an intra-
articular corticosteroid joint injection [31]. Polyarticular
joint involvement is a predictor of OA progression, not
necessarily of the clinical response.
5.2 Biochemical Biomarkers
A systematic review of serum and urine biomarkers in knee
and hip OA provides an overview of publications on bio-
chemical markers performance [32]. Data were categorized
according to the five categories of the BIPED classification
proposed by the National Institutes of Health (NIH)-funded
OA Biomarkers Network [33]: Burden of disease, Inves-
tigative, Prognosis, Efficacy of intervention, and Diagnos-
tic. A total of 26 biochemical markers were identified, 15
concerned collagen metabolism, eight related to collagen
type Il degradation (CTX-II, HELIX-11, C2C, Coll2-1,
Coll2-1 NO(2), TIINE) and synthesis (PIIANP, PIICP),
five to collagen type 1 degradation (NTX-1, CTX-1, ICTP)
and synthesis (PICP, PINP), one to collagen type I and ll
degradation (C1, 2C), and one to collagen type III synthesis
(PIIINP). It was concluded that none of the current bio-
chemical markers, of cartilage, bone, or synovial metabo-
lism, is sufficiently discriminating to aid diagnosis and
prognosis in individual patients with OA, to facilitate the
design of clinical trials or to act as a surrogate outcome
used as an additional secondary endpoint. This is a view
shared by the ESCEO working meeting on biomarkers [7].
However, it must be taken into account that the current
perceived limitations in the use of biomarkers stems in part
from the limited tools available for their qualification, i.e.,
the means of establishing the context in which they are
validated.
A nested case–control study of progressive knee OA
within the OsteoArthritis Initiative has been initiated by the
Foundation of NIH OA Biomarkers Consortium to deter-
mine the biomarkers with optimal predictive validity and
responsiveness for progression of knee OA [5]. The 12
assessed biochemical markers are related to cartilage
degradation (CTX-II, C1, 2C, C2C, Coll2-1NO2 in urine
and COMP, C1, 2C, C2C, CPII, PIIANP, CS846, MMP-3
in serum), bone resorption [serum and urine NTX-I and
CTX-I), and synovitis (serum hyaluronic acid (HA)]. The
next step should be the qualification of the most promising
markers, either prospectively or using data from completed
clinical trials.
5.3 Genetic and Epigenetic Markers
New technologies are now available to investigate the link
between cellular mechanisms and the disease phenotypes,
including the omics approach (genomomics, transcrip-
tomics, proteomics, epigenomics, microbiomics, metabo-
lomics) the exposome (the combined exposures from all
sources received by a person during life), new non-hier-
archical approaches to phenotyping complex disease (e.g.,
cluster analyses), applications of informatics to interrogate
large data-sets from biological collections, clinical trials,
and linked population-based case records and prescribing
practice.
A genetic component to OA in most of the large joints
has been established [34]. Recent developments of the
identification of the susceptibility genes for OA by using
different approaches including genome-wide association
studies, family-based studies, and extreme OA phenotypes
have been recently reviewed, showing rapid progress in the
knowledge of genetics of OA. Despite numerous efforts
made on human genetic studies worldwide, only a few
numbers of loci have been associated with OA. This might
be attributed to several factors such as insufficient sample
sizes and disease heterogeneity that might result from
different underlying causes, both genetic and environ-
mental, depending on which joints are affected [35]. OA is
a complex polygenic disease that lacks any large-effect
susceptibility loci. Instead, OA susceptibility alleles indi-
vidually contribute only modestly to the overall disease
risk, making their identification challenging. Although the
success of genetic studies is still limited, recent data sug-
gest that epigenetic mechanisms may be heavily mecha-
nistically involved [36].
5.4 Genetic Biomarkers
In a recent meta-analysis of nine genome-wide association
studies using Human Genome Epidemiology (HuGE)
navigator in patients with knee and hip OA, only 2 of the
199 candidate genes considered were shown to be associ-
ated with hip OA: COL11A1 (collagen, type XI, alpha 1)
and vascular endothelial growth factor (VEGF, signal
found only in men) [37].
Other examples are:
• That genetic modification of the SMAD3 gene was
found to be associated with hip and knee OA in
European populations [38], and also with hand and
knee OA in a northeast Chinese population [39];
• TRPV1 (transient receptor potential cation channel,
subfamily V, member 3) and COMT (catechol-O-
methyltransferase) variants are involved in the percep-
tion of pain in knee OA [40, 41];
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• FTO (fat mass and obesity-associated) signal is robustly
associated with BMI, and showed evidence of associ-
ation with OA underpinning the known epidemiolog-
ical link between BMI and OA [42];
• The IL1RN (interleukin-1 receptor antagonist) C-T-A
haplotype may have a role in severe knee OA which is
consistent with the possible role of IL-1 as a regulator
of cartilage degradation [43];
• COL11A1, which could play a role in erosion of joints
cartilage in OA, is a strong candidate gene for OA [44];
• GDF5 (Growth and differentiation factor 5), to promote
the development, maintenance, and repair of joint
tissues is associated with OA of the knee with genome-
wide statistical significance [45];
• The Semaphorin 4D (Sema4D) gene region may play a
role in the etiology of acetabular dysplasia [46], a
multifactorial disease that has been shown to increase
the risk of OA [47].
Moreover, studies are being set up to unravel the genetic
causes of OA, including a 5-year study by Arthritis
Research UK focusing on rare genetic variants that lead to
the development of OA, and looking at how they interact
with environmental factors to increase the risk of devel-
oping OA.
5.5 Epigenetic Biomarkers
Although limited compared with genetic studies, epigenetic
studies suggest that post-transcriptional regulation of gene
expression might play a substantial role in OA progression.
In particular, microRNA-mediated mechanisms have been
found to be differentially expressed in normal and OA
cartilage [48, 49] and offer potential diagnostic and ther-
apeutic strategies, which need to be further investigated.
6 Frailty and OA
6.1 The Frailty Phenotype
In patients with OA, the presence of coexistent chronic
conditions, particularly heart disease, pulmonary disease,
and obesity, increase markedly the likelihood of subse-
quent disability [50]. Consequently, there is a need to
assess comorbidity, which is one of the main risk factors
for frailty.
There is a growing consensus that comorbidity, dis-
ability, and frailty are distinct clinical entities with distinct
prevention and therapeutic issues, important overlap, and a
causal relationship [51]. Frailty is generally described as ‘‘a
multidimensional syndrome characterized by decreased
reserve and diminished resistance to stressors’’ [52]. There
are two main ways of defining frailty: the Cardiovascular
Health Study index [53] defines frailty as a clinical syn-
drome in which three or more of the following phenotype
indicators are present: unintentional weight loss, self-re-
ported exhaustion, weakness, slow walking speed, and low
physical activity. Alternatively, the Geriatric Status Scale
[54] combines aspects of cognitive and functional perfor-
mance to describe various degrees of frailty from ‘‘robust’’
to ‘‘severely frail’’ to predict death or need for institutional
care.
In the SHARE study, a multidisciplinary European
Union Research project, the prevalence of frailty and pre-
frailty in 18,227 randomly selected community-dwelling
men and women aged 50 years and older reached around
10 and 50 %, respectively [55]. In four large prospective
cohort studies, frailty was shown to be associated with all
negative outcomes (falls, disability, hospitalization, home
care admission, mortality) [56]. A study based on data from
cohorts of community-dwelling persons aged 65 years or
older showed that adding frailty markers to age, sex, and
chronic diseases provided an increase in the patient-level
prediction of disability [57]. The increase was modest but
worthwhile because frailty is potentially a reversible con-
dition when effective interventions are put in place [58].
There is thus an urgent need to identify pre-frail and frail
older adults to prevent rapid disability in our OA aging
population [59].
6.2 Association of OA with Frailty Status
Comorbidity and frailty status affect the treatment of OA in
many different ways, including the ability to adhere to
exercise, polypharmacy (with the potential for drug–drug
interactions and increased risk of adverse events), medical
contraindications, worsening of quality of life, and mood
disorders such as depression and anxiety that can accom-
pany any chronic condition. Several studies have recently
examined the association of OA with frailty, all suggesting
that the frailty status should be assessed when considering
treatment of OA, as it may be essential in targeting ther-
apeutic interventions. The EPOSA study (2942 patients
aged 65–85 years) showed a significant association
between clinical OA at any site and frailty status (prelim-
inary results). In a cohort of 4130 men aged over 65 years,
hip OA and total hip replacement were found to be asso-
ciated with greater frailty, suggesting that interventions to
reduce frailty should be evaluated in these patients [60].
People with lower extremity OA had a two to five times
increased incidence of falls than age-matched healthy
controls [61]. The mechanisms underlying this increased
risk are not clear but could involve poor physical perfor-
mance, loss of proprioception, and impaired balance [62,
63]. Another study showed that clinical frailty significantly
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predicted mortality in subjects with OA. Thus, clinical
frailty may be considered a new prognostic factor to
identify subjects with OA at high risk of mortality [64].
The intervention will need to be targeted to the exact
phenotype of the frailty identified.
6.3 Ongoing Projects with a Strong Potential
for Synergies and Complementarities
in the Fields of Frailty and OA
There are several international projects in progress that
have the potential to further advance the importance and
understanding of the interaction between OA and frailty.
The Innovative Medicines Initiative (IMI), a joint under-
taking between the European Union and the pharmaceuti-
cal industry association EFPIA, is supporting the
SPRINTTPROJECT (Sarcopenia and Physical Frailty in
older people: multi-component treatment). The IMI is
additionally funding the APPROACH (Applied Public–
Private Research enabling OsteoArthritis Clinical Head-
way) project, which will enhance the collective knowledge
base around OA biomarkers and disease as well as build
stronger collaborations among academic and industrial
groups to enable effective therapeutic development. The
‘‘European Innovation Partnership on Active and Healthy
Ageing’’ project promotes systematic routine screening for
pre-frailty stages in at-risk patients and older people using
the Mmultidimensional Prognostic Index [65]. This index
is a multidimensional tool measuring frailty and prognostic
indicators in health-related outcomes.
7 Conclusions
Our increasing knowledge of disease and drug mechanisms
has led to the understanding that the heterogeneity in dis-
ease expression and response to therapy is the result of
differing underlying pathological mechanisms, as well as
other individual patient features that influence treatment
efficacy and tolerability. Considering the heterogeneous
nature of OA, the very large number of affected individ-
uals, and the need for new efficient and safe treatments, OA
appears as an optimal candidate for personalized healthcare
[66].
The ultimate aim of these discussions of the ESCEO
working group was to explore the value of (bio)markers of
different sources in defining different phenotypes of
patients with OA. The characterization of the OA patient
phenotype could be used to guide clinical decision making.
Optimizing the selection of patients for whom an inter-
vention with a DMOAD could prevent the development of
OA would assist the emergence of personalized or preci-
sion medicine for these patients.
A research agenda for the identification of patient phe-
notypes was proposed (Table 1). This approach should lead
to the definition of a risk score, allowing the categorization
of patients according to their risk for structural or clinical
progression. This should include all possible predictors,
possibly including an aggregate of different (bio)markers.
As part of this agenda, it was felt important to recom-
mend a core data set that should be collected in future
studies of OA that assesses the natural history of the dis-
ease and the response to treatment. This will allow more
standardized assessment and collation of cohorts and
databases in the future. Following the meeting, the working
group produced a recommended list of core data, presented
in Table 2, which was based on the evidence provided at
the meeting and individual expert opinion.
Profiles of patients may be defined according to their
level of pain, functional limitation, and presence of coex-
istent chronic conditions including frailty status. Moreover,
converging data argue for an MRI-based diagnosis in
clinical practice to help physicians identify patients who
are more likely to benefit from treatment. More research is
required, however, to validate these preliminary findings
and to correlate improvements with hard clinical endpoints.
Among potential biochemical biomarkers, despite active
research and numerous candidates, none is sufficiently
validated and recognized for systematic use in drug
development of OA or in clinical practice to identify
patients who should be treated. Among current investiga-
tions, the Foundation of NIH OA Biomarkers Consortium
has established and initiated a process for validation and
qualification of the most promising commercially available
biomarkers in OA [5]. This approach will support new drug
Table 1 Research agenda for the identification of patient phenotypes
Identify published randomized clinical trials and observational
cohorts assessing the efficacy of different class of interventions
on clinically relevant outcomes, divided in structural and
symptomatic outcomes
Using above data, produce clinical prediction tools to quantify a
patient’s risk of progression and good outcomes from treatment
interventions
With available data, identify phenotypes of patients according to
their outcome. Panel of (bio)markers (clinical, biochemical,
imaging) should be investigated, rather than individual items
Assess the uniformity of data across clinical trials and cohorts
Proceed to a validation step on a separate validation cohort
Ensure that all new cohorts and trials use the same core dataset to
allow easy integration into extant data
Possible limitations:
The availability of the data and of the biological specimens in
cohorts
The high heterogeneity in the assessments methods and reporting
(e.g., multiple assessment tools for pain), which would require
a hierarchical/standardization of criteria
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developments, preventive medicine, and medical diagnos-
tics for OA.
In the future, identification of genes associated with OA
may help reveal underlying biological mechanisms that
lead to the development of new therapeutic targets or
biomarkers for early detection and risk stratification.
Considerable efforts are being made to identify genetic and
epigenetic factors involved in OA that could be used as
potential stratifiers, but results are still limited. However,
with new technologies, diagnosis will increasingly focus on
integrating information for multiple sources, not only
genomics and other omics technologies but also environ-
mental and lifestyle data.
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